| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Accounting & tax | 22,551 | 0 | 0 | 0 |
| Audit expense | 15,000 | 0 | 0 | 0 |
| Identifier | Return Reference | Explanation |
|---|---|---|
| General Explanation Supplemental Information for Form 990-PF | Expenditure Responsibility StatementPart VII-B Line 5CGrantee's Name: CK-12Grantee's Address: 1760 The Alameda Suite 300, San JoseGrant Amount: $10,750,000.Date of Grant: Various 2020Amount Expended: $10,750,000.Purpose of Grant:To directly support the activities of the CK12 Foundation to develop and operate an open educational source for teaching, learning and research resources that reside in the public domain or have been released under an intellectual property license that permits their free use or repurposing by others.The Executive Director of the Grantee is the President of the Grantor. All expenditures and reports are monitored in real time. Of the $10,750,000 given in 2020, all was used for the stated purpose.To the knowledge of the Grantor, no funds have been diverted to any activity other than activity for which the grant was originally made.Any Diversion by Grantee: NoneResults of Verification:The Grantor has no reason to doubt the accuracy or reliability of the report from the Grantee; therefore no independent verification of the report was made. | |
| General Explanation Supplemental Information for Form 990-PF | Expenditure Responsibility StatementPart VII-B Line 5CGrantee's Name: Augmenta Bioworks, Inc.Grantee's Address: 3475 Edison Way, Unit K, Menlo Park, CA 94025Grant Amount: $500,070Date of Grant: 11/5/2020Amount Expended: $290,000.Purpose of Program related investments:To directly provide support for profiling immunity of patients with Chronic Fatigue Syndrome and health patients. To the knowledge of the Grantor, no funds have been diverted to any activity other than activity for which the grant was originally made.Based upon the 2020 Annual report received from Augmenta Bioworks, Inc. dated 7/27/21, the total amount of $397,501 was expensed for the related program.Any Diversion by Grantee: NoneResults of Verification:The Grantor has no reason to doubt the accuracy or reliability of the report from the Grantee; therefore no independent verification of the report was made. |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| 13,516 | 0 | 0 | 0 |
| Description | Beginning of Year - Book Value | End of Year - Book Value | End of Year - Fair Market Value |
|---|---|---|---|
| Augmenta program investment | 200,000 | ||
| Distribution receivable | 1,021 | ||
| Kashf Holding (PRI) | 229,000 | 229,000 | |
| Loan to Cortene, Inc. | 200,000 | 200,000 | 245,375 |
| Loan to OMI (PRI) | 3,173,000 | 3,173,000 | |
| Partnership Commitments | 15,000 | ||
| Rounding | 1 | ||
| Short-term receivable | 61,605 | ||
| Unitus Seed Fund (PRI) | 136,195 | 118,399 | 126,185 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Other nondeductible | 1 | |||
| Passthrough expenses | 9,464 | 9,464 |
| Description | Amount |
|---|---|
| Rounding | 3 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Federal tax | 238,000 |